{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:51:25Z","timestamp":1790207485048,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.carrev.2025.02.001","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T11:34:08Z","timestamp":1738668848000},"page":"11-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical safety and performance of the third-generation Fantom Encore sirolimus-eluting bioresorbable scaffold: Insights from a single-center study"],"prefix":"10.1016","volume":"82","author":[{"given":"Francesco","family":"Amata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mangieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Regazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Reimers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2025.02.001_bb0005","doi-asserted-by":"crossref","unstructured":"-Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015;385(9962):43\u201354.","DOI":"10.1016\/S0140-6736(14)61455-0"},{"issue":"11","key":"10.1016\/j.carrev.2025.02.001_bb0010","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.4244\/EIJ-D-20-00024","article-title":"Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial","volume":"16","author":"Onuma","year":"2020","journal-title":"EuroIntervention"},{"key":"10.1016\/j.carrev.2025.02.001_bb0015","series-title":"Presented at: EuroPCR 2018; May 22\u201325, 2018; Paris, France","article-title":"Tyrocore: a proprietary polymer uniquely designed for vascular scaffolds","author":"Leibundgut","year":"2018"},{"key":"10.1016\/j.carrev.2025.02.001_bb0020","unstructured":"-Leibundgut G. A novel, radiopaque, bioresorbable tyrosine-derived polymer for cardiovascular scaffolds. European Featured Technology. 2018. Available online: https:\/\/citoday.com\/articles\/2018-july-aug\/a-novel-radiopaque-bioresorbable-tyrosine-derived-polymer-for-cardiovascular-scaffolds?c4src=archive:feed. [Accessed 3 Oct 2024]."},{"issue":"7","key":"10.1016\/j.carrev.2025.02.001_bb0025","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.4244\/EIJ-D-23-00504","article-title":"Long-term safety and effectiveness of the Fantom bioresorbable coronary artery scaffold: final results of the FANTOM II trial","volume":"20","author":"Lutz","year":"2024","journal-title":"EuroIntervention"},{"issue":"2","key":"10.1016\/j.carrev.2025.02.001_bb0030","first-page":"424","article-title":"Usability of Fantom Encore\u00ae scaffold in non-complex bifurcations-analysis in bench models","volume":"99","author":"Toth","year":"2022","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.carrev.2025.02.001_bb0035","first-page":"E1","article-title":"Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: baseline OCT and 30-day clinical outcomes - a FANTOM STEMI pilot study","volume":"96","author":"Koltowski","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2025.02.001_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmbbm.2021.104955","article-title":"An experimental investigation into the physical, thermal and mechanical degradation of a polymeric bioresorbable scaffold","volume":"125","author":"Fiuza","year":"2022","journal-title":"J Mech Behav Biomed Mater"},{"issue":"24","key":"10.1016\/j.carrev.2025.02.001_bb0045","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.025275","article-title":"Utility of the ACC\/AHA lesion classification to predict outcomes after contemporary DES treatment: individual patient data pooled analysis from 7 randomized trials","volume":"11","author":"Konigstein","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"10096","key":"10.1016\/j.carrev.2025.02.001_bb0050","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(17)31470-8","article-title":"2-Year outcomes with the absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy","volume":"390","author":"Ali","year":"2017","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.carrev.2025.02.001_bb0055","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4244\/EIJ-D-17-00873","article-title":"Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II trial)","volume":"13","author":"Chevalier","year":"2018","journal-title":"EuroIntervention"},{"issue":"18","key":"10.1016\/j.carrev.2025.02.001_bb0060","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jcin.2017.07.033","article-title":"6-month clinical and angiographic outcomes of a novel radiopaque Sirolimus-eluting Bioresorbable vascular scaffold: the FANTOM II study","volume":"10","author":"Abizaid","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.carrev.2025.02.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000941","article-title":"Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study","volume":"6","author":"Simonsen","year":"2019","journal-title":"Open Heart"},{"issue":"6","key":"10.1016\/j.carrev.2025.02.001_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.007283","article-title":"Clinical and angiographic outcomes with a novel radiopaque sirolimus-eluting bioresorbable vascular scaffold","volume":"12","author":"Chevalier","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2025.02.001_bb0075","article-title":"TCT CONNECT-270 FANTOM II trial: safety and performance study of the fantom sirolimus-eluting bioresorbable coronary scaffold\u2014first report: 4-year clinical outcomes","volume":"76(17 Supplement S):B118","author":"Lutz","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.carrev.2025.02.001_bb0080","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10557-023-07429-0","article-title":"Third-generation Sirolimus-eluting Bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: baseline and 6-month OCT and clinical outcomes-a FANTOM STEMI pilot study","volume":"38","author":"Koltowski","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.carrev.2025.02.001_bb0085","unstructured":"-Daemen J. Safety and efficacy of the FANTOM ENCORE sirolimus-eluting bioresorbable scaffold for treatment of de-novo coronary artery disease: The ENCORE-I study [Clinical trial]ClinicalTrials.gov. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04591938"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838925000429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838925000429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:24:00Z","timestamp":1770855840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838925000429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":17,"alternative-id":["S1553838925000429"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2025.02.001","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical safety and performance of the third-generation Fantom Encore sirolimus-eluting bioresorbable scaffold: Insights from a single-center study","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2025.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}